Cancers are routinely classified into subtypes according to various fea-1 tures, including histo-pathological characteristics and molecular markers. Previous 2 genome-wide association studies have reported heterogeneous association between 3 loci and cancer subtypes. However, it is not evident what is the optimal modeling 4 strategy for handling correlated tumor features, missing data, and increased degrees-5 of-freedom in the underlying tests of associations. We propose score tests for genetic 6 associations using a mixed-effect two-stage polytomous model (MTOP). In the first 7 stage, a standard polytomous model is used to specify for all subtypes defined by 8 the cross-classification of different markers. In the second stage, the subtype-specific 9 case-control odds ratios are specified using a more parsimonious model based on 10 the case-control odds ratio for a baseline subtype, and the case-case parameters as-11 sociated with tumor markers. Further, to reduce the degrees-of-freedom, we specify 12 case-case parameters for additional exploratory markers using a random-effect model. 13 We use the Expectation-Maximization (EM) algorithm to account for missing data 14 on tumor markers. Through simulations across a range of realistic scenarios and data 15 from the Polish Breast Cancer Study (PBCS), we show MTOP outperforms alterna-16 tive methods for identifying heterogeneous associations between risk loci and tumor 17 subtypes.
I. INTRODUCTION
study. D i = 0 represents a control, and D i = m represent a subject with disease of subtype 99 m. Let G i be the genotype for ith subject and X i be a P × 1 vector of other covariates 100 we want to adjust for in the model, where P is the total number of other covariates. we 101 first build the standard "saturated" polytomous logistic regression model as the first stage 102 model,
, m ∈ {1, 2, · · · , M },
6 where β m and η m are the regression coefficients for a SNP and other covariates associated 104 with the mth subtype, repsectively.
105
Because each cancer subtype m is defined through a unique combination of the K 106 characteristics, we can always alternatively index the parameters β m as {β s 1 s 2 ···s K }, where 107 s k ∈ {0, 1} for binary tumor characteristics, and s k ∈ {t 1 ≤ t 2 ≤ · · · ≤ t M k } for ordinal 108 tumor characteristics with t 1 , . . . , t M k as a set of ordinal scores for M k different levels. With 109 this new index, we can represent the log odds ratio defined in first stage model as
Here θ (0) represents the case-control log odds ratio for a reference disease subtype compared 111 to the control, θ
k 1 represent the main effect of k 1 th tumor characteristic, θ
k 1 k 2 represent the 112 second order interaction between k 1 th and k 2 th tumor characteristics and so on. A reference 113 level could be defined for each tumor characteristic, and the reference disease subtype is 114 jointed defined by the combination of the K tumor characteristics. 115 The reparameterization in 2 provides a way to decompose the first stage parameters to 116 a lower dimension. We can constrain different main effects or interaction effects to be 0 to 117 specify different second stage models. We can link the first stage parameters and second stage 118 parameters with a matrix form,
is a vector of first stage case-control log odds ratios for all the M subtypes, θ (0) is the 120 case-control log odds ratio for the reference subtype, θ H is the vector containing all the 121 main effects and interactions effects in the second stage. We will also refer θ H as case-case 122 parameters in the later paper. And θ = (θ (0) , θ T H ) T is the vector of second stage parameters. tumor subtypes, which can be denoted as
and that the tumor characteristics are missing at random. Let δ = (θ T , λ T ) T , where δ 173 represent the second stage parameters of both G and X. Given the notation above, the EM 174 algorithm at the vth iteration would be:
where Y E im is the probability of the ith person to be of the mth subtype given his observed 177 tumor characteristics, genotype and other covariates. I(Y im ∈ Y io ) denote whether the mth 178 subtype for the ith subject belong to the subsets of possible subtypes given the observed 179 tumor characteristics.
180
M step:
The M step could be solved through a weighted least square iteration. Let 
where P (t) and 186 W (l) uses the same definition as P and W evaluated at the δ (t) . The weighted least square 
. The corresponding efficient information matrix of 217 U θ (λ) is:
where
The score test statistics Q θ for fixed-effect two stage model would be: 
where Z f is the second stage design matrix of fixed effect, Z r is the second stage design matrix 235 of random effect, and θ f are the fixed-effect second stage parameters. be: H EH 0 : θ fH = 0, σ 2 = 0 versus H EH 1 : θ fH = 0 or σ 2 = 0.
250
To derive the score statistics for under the global null H A 0 : θ f = 0, σ 2 = 0 , the common 251 approach is to take the partial derivatives of loglikelihood with respective to θ f and σ 2 re-252 spectively. However, under the null hypothesis, the score for θ f follows a normal distribution 253 and for σ 2 follows a mixture of chi-square distribution (see more details in Supplementary   254 Section 3). With the correlation between the two scores, getting the joint distribution be-255 tween the two becomes very complicated. Inspired by methods for the rare variants testing 256 (Sun et al., 2013) , we propose to modify the derivations of score statistics so that we can get 257 two independent scores. First for θ f , we derive the score test statistics Q θ f under the global 258 null hypothesis H A 0 : θ f = 0, σ 2 = 0 as usual. But for the score test statistics for σ 2 , we 259 derived the the score statistics Q σ 2 under the null hypothesis H 0 : σ 2 = 0 without constrain-260 ing θ f . Through this procedure, the two score test statistics Q θ f and Q σ 2 can be proved as The score statistics of fixed effect θ f under the global null H A 0 : θ f = 0, σ 2 = 0 would be:
where of freedom l f is the same as the length of θ f .
269
To explicitly express the Q σ 2 , let τ = (θ T f , λ T ) T be the second stage fixed effect, and Z τ 270 is the corresponding second stage design matrix. The variance component score statistics of 271 σ 2 under the null hypothesis: H 0 : σ 2 = 0 without constraining θ f would be:
where P r = E σ 2 =0 (Y|G, X;τ ) , andτ is the MLE under the null hypothesis: H 0 : σ 2 = 0. 
The weighted matrix W r has the same definition as in Section II C , but 277 evaluated under the null hypothesis H 0 : σ 2 = 0. The Davies exact method (Davies, 1980) 278 is used here to calculate the p-value of the mixture of chi square distribution.
279
To use Fisher's procedure to combine the p-value coming out from the two indepent score 280 test statistics. Let P θ f = P r(Q θ f ≥ χ 2 l f ) and P σ 2 = P r(Q σ 2 ≥ s i=1 ρ i χ 2 i,1 ). Under the null 281 hypothesis H A 0 : θ f = 0, σ 2 = 0, −2 log(P θ f ) − 2 log(P σ 2 ) follows χ 2 4 . Then the p-value P mix 282 of mixed effect two-stage model score test under the null hypothesis would be:
15
The extension of the score statistics to global test for etiology heterogeneity, H EH 0 : θ fH = 284 0, σ 2 = 0, would be straightforward. and all the other three case-case parameters were set to follow a normal distribution with 340 mean 0 and variance 4 × 10 −4 . Under this scenario, all the tumor characteristics contribute 341 18 subtype-specific heterogeneity. The total sample size n was set to be 25,000, 50,000, and 342 100,000. We performed 10 5 simulations to evaluate the power at α < 10 −3 level. 343 We compared the statistical power to detect the genetic association between MTOP, 344 FTOP, a standard logistic regression, polytomous logistic regression, and a two-stage model 345 that only uses cases with complete tumor characteristics. the cases have at least one tumor characteristics missing. We performed 10 5 simulations to 359 evaluate the power at α < 10 −3 level. In this section, we used data from the PBCS, a population-based breast cancer case-386 control study conducted in Poland between 2000 and 2003 (García-Closas et al., 2006 .
387
The study population consisted of 2,078 cases of histologically or cytologically confirmed 388 invasive breast cancer, and 2,219 women without a history of breast cancer at enrollment.
389
Tumor characteristic information on ER, PR, and grade were available from pathology 390 records (García-Closas et al., 2006) and information on HER2 status was available from 391 immunohistochemical staining of tissue microarray blocks (Yang et al., 2007) . We used 392 genome-wide genotying data to compare MTOP, FTOP, standard logistic regression, and 393 polytomous logistic regression to detect SNPs associated with breast cancer risk.
394 Table II plots of the four GWAS analysis can be found in Supplementary Figure 1 . 416 Next, we compared the ability of the same MTOP and standard logistic regressions to 417 detect 178 previously identified breast cancer susceptibility loci (Michailidou et al., 2017) .
418
As shown in Table III We present a series of novel methods for performing genetic association testing for can-426 cer outcomes accounting for potential heterogeneity across subtypes defined by multiple, Heterogeneity test for a tumor marker was applied with only FTOP. All of the type error rates are divided by the α level.
MTOP FTOP
Interested tests Total sample size α = 10 −4 α = 10 −5 α = 10 −6 α = 10 −4 α = 10 −5 α = 10 respectively. Around 70% cases would be incomplete. The total sample size was set as 25,000, 50,000 and 100,000. The case control ratio was 1:1. 
